Ji H, Moritz R L, Reid G E, Ritter G, Catimel B, Nice E, Heath J K, White S J, Welt S, Old L J, Burgess A W, Simpson R J
Joint Protein Structure Laboratory, Ludwig Institute for Cancer Research (Melbourne Branch), Parkville, Victoria, Australia.
Electrophoresis. 1997 Mar-Apr;18(3-4):614-21. doi: 10.1002/elps.1150180345.
The murine monoclonal antibody A33 (mAbA33) recognises a human cell membrane-associated antigen selectively expressed in epithelial cells of the lower gastrointestinal tract and > 90% of colonic cancers, but is not detected in a wide range of other normal tissues by immunohistochemical analysis. In phase I/II clinical triasl, mAbA33 has been shown to target advanced colon cancers and the humanized version is currently being evaluated in therapy studies. Although the mAbA33 has been well characterised by immunohistochemical and clinical studies, until recently, the target antigen has remained poorly defined. This was largely attributable to the antigenic determinant recognised by mAbA33 being dependent on the native spatial conformation of the A33 antigen which impeded its identification by conventional two-dimensional electrophoresis (2-DE) and immunoblot analysis. We have developed an immunoblot method, based on nonreducing/non-urea precast 2-DE gels, that has facilitated the purification of the detergent (0.3% Triton X-100) solubilised A33 antigen from the human colon cancer cell lines LIM1215 and SW1222. Under these 2-DE conditions, the A33 antigen electrophoreses with an apparent M(r) approximately 41000 and pI 5.0-6.0. Attempts to isolate the A33 antigen from 2-DE gels for direct structural analysis were unsuccessful, due to its co-electrophoresis with actin and cytokeratin proteins. However, using Western blot and biosensor detection the A33 antigen has been purified chromatographically and N-terminal sequence analysis was possible. Using polyclonal antibodies raised against a synthetic peptide corresponding to the N-terminal region of the A33 antigen we have used Western blot analysis to localise the molecule in our master 2-DE protein database for normal human colon crypts and several colon carcinoma cell lines (URL address: http:(/)/www.ludwig.edu.au). Under reducing 2-DE conditions, the A33 antigen electrophoresis as 6 differentially charged isoforms (pI 4.6-4.8) with a single molecular weight species at M(r) approximately 55000.
鼠单克隆抗体A33(mAbA33)可识别一种人细胞膜相关抗原,该抗原在下消化道上皮细胞和90%以上的结肠癌中选择性表达,但通过免疫组织化学分析在多种其他正常组织中未检测到。在I/II期临床试验中,mAbA33已被证明可靶向晚期结肠癌,其人源化版本目前正在治疗研究中进行评估。尽管mAbA33已通过免疫组织化学和临床研究得到充分表征,但直到最近,其靶抗原仍未得到很好的定义。这主要归因于mAbA33识别的抗原决定簇依赖于A33抗原的天然空间构象,这阻碍了通过传统二维电泳(2-DE)和免疫印迹分析对其进行鉴定。我们开发了一种基于非还原/非尿素预制2-DE凝胶的免疫印迹方法,该方法有助于从人结肠癌细胞系LIM1215和SW1222中纯化去污剂(0.3% Triton X-100)溶解的A33抗原。在这些2-DE条件下,A33抗原以约41000的表观分子量(M(r))和5.0 - 6.0的等电点(pI)进行电泳。由于A33抗原与肌动蛋白和细胞角蛋白共电泳,从2-DE凝胶中分离A33抗原以进行直接结构分析的尝试未成功。然而,使用蛋白质印迹法和生物传感器检测,A33抗原已通过色谱法纯化,并且可以进行N端序列分析。使用针对与A33抗原N端区域相对应的合成肽产生的多克隆抗体,我们利用蛋白质印迹分析将该分子定位在我们用于正常人结肠隐窝和几种结肠癌细胞系的主2-DE蛋白质数据库中(网址:http://www.ludwig.edu.au)。在还原2-DE条件下,A33抗原电泳为6种带不同电荷的异构体(pI 4.6 - 4.8),单一分子量物种的分子量约为55000。